Evaluation 2 of "Accelerating Vaccine Innovation for Emerging Infectious Diseases via Parallel Discovery"

Tim Colbourn

No 2024-12, The Unjournal Evaluations from The Unjournal

Abstract: This paper tackles an important global priority area. The main limitations are the premise being restricted to private sector investment, and parameter values used. A societal perspective including (up to 100%) publicly owned efforts, and different reasonable parameter value assumptions, including optimising number of vaccine candidates in relation to expected outbreaks and infections, would alter the conclusions. Calculating cost per QALY gained, and in relation to current healthcare expenditure, would further strengthen the paper.

Date: 2024-03-05
References: View references in EconPapers View complete reference list from CitEc
Citations:

Published in The Unjournal

Downloads: (external link)
https://unjournal.pubpub.org/pub/accelvaxeval2 (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:bjn:evalua:accelvax-e2

DOI: 10.21428/d28e8e57.59b7c04e/89842a46

Access Statistics for this paper

More papers in The Unjournal Evaluations from The Unjournal
Bibliographic data for series maintained by Davit Jintcharadze ().